ABSTRACT Protective immunity against avian influenza (AI) virus has been elicited in chickens by singledose in ovo or i.m. vaccination with a replication-competent adenovirus (Ad)-free human Ad vector encoding the AI virus A/Turkey/Wisconsin/68 H5 (AdTW68. H5) or the A/Chicken/New York/94 H7 (AdChNY94. H7) hemagglutinin (HA). The AdTW68.H5-vaccinated chickens were protected against both H5N1 and H5N2 highly pathogenic AI virus challenges. The AdChNY94. H7-vaccinated chickens were protected against an H7N3 highly pathogenic avian influenza virus challenge. Chickens vaccinated in ovo with AdTW68.H5 followed by posthatch i.m. vaccination with AdChNY94.H7 responded to both vaccinations, with robust antibody titers against both the H5 and H7 AI proteins. The use of a synthetic AI H5 HA gene codon optimized to match the tRNA pool found in chicken cells is more potent than the cognate H5 HA gene. Mass administration of this AI vaccine can be streamlined with available robotic in ovo injectors. In addition, Ad5-vectored vaccines can be produced rapidly and the safety margin of the nonreplicating vector is superior to that of a replicating counterpart. Furthermore, this mode of vaccination will not interfere with epidemiological surveys of natural AI infections. Finally, the demonstration that Ad-vectored vaccines can be administered repeatedly without appreciably losing potency highlights the commercial potential of this new class of vaccine in poultry.
INTRODUCTION
Highly pathogenic avian influenza (HPAI) viruses belonging to the H5 or H7 types continue to threaten the world poultry industry and are zoonotic agents with pandemic potential for humans (Ungchusak et al., 2005) . Strategies to control avian influenza (AI) vary from none for low pathogenic AI virus strains to the other extreme of implementing a slaughter approach during an HPAI outbreak. This radical approach is feasible when AI occurs in restricted areas with adequate veterinary infrastructure, but the costs can be insurmountable if viral infections are widespread. From the perspective of human health it seems reasonable to predict that increased resistance to AI in global poultry populations would greatly reduce the risk of a pandemic in humans. In December 2005 the World Organization for Animal Health and the Food and Agriculture Organization of the United Nations recommended that vaccination of poultry be considered for the control of AI viruses (OIE/FAO, 2005) .
VACCINATION AGAINST AI
Mass vaccination increases the resistance of chicken populations and reduces viral shedding. Ideal AI vaccines should not only meet the normal requirements for all poultry vaccine products (i.e., induction of protective immunity, cost-effectiveness, safety in the food chain, and feasibility for mass delivery, etc.) but also comply with a DIVA (differentiation between infected and vaccinated animals) strategy and increased biosafety regulations both at vaccine production centers as well as in the field. Numerous vaccines, both commercially available and experimental, are capable of inducing an appropriate level of protective immunity in chickens. Live AI vaccines prepared using naturally avirulent or attenuated strains are associated with an inherent risk for generating new reassortant influenza viruses (Hilleman, 2002) with unpredictable characteristics. These reassortants could arise when a host bird is simultaneously infected with both the live AI vaccine and another influenza virus.
Conventional whole AI virus inactivated vaccines induce appropriate immunity but have serious disadvantages such as incompatibility with DIVA, withdrawal time of as long as 42 d, individual delivery, and the biohazard during manufacturing. In addition, the vaccine production process is difficult due to high lethality of most influenza virus strains for chicken embryos. Inactivated marker vaccines (Capua et al., 2000) overcome only some of these disadvantages.
RECOMBINANT VACCINES
Multiple experimental recombinant vaccines have been developed in recent years, some of which have been reported to efficiently protect chickens against HPAI (e.g., Swayne, 2003; Lee et al., 2004; Park et al., 2006) . The distinct advantage of vectored vaccines is the ability to introduce highly specific immune interventions based on well-defined antigens that can be the focus of specific immune reactivity. Evidence shows that vaccination of chickens by delivery of a fowl pox vector encoding a specific AI virus hemagglutinin (HA) is sufficient to protect immunized birds against lethal AI virus challenges. The homology between the HA of the vaccine and that of the challenge virus is inversely correlated with virus shedding in poultry (Swayne et al., 2000b) ; however, a broad cross-protection within a subtype between even antigenically diverse AI viruses might be achievable among chickens (Swayne et al., 2000c) . Although multiple vectors are available as vaccine carriers, bioengineered avian virus-derived vectors based on viruses that are endemic in the poultry industry (e.g., fowl pox virus) have shown reduced protection associated with preexisting immunity to the vector due to preexposure of birds to the avian virus (Swayne et al., 2000a) . Other disadvantages of some live recombinant vaccines include the risk of generating revertants and allow spread of genetically modified organisms in both target and nontarget species in the environment.
Because of the disadvantages of available AI vaccines, a new generation of AI vaccine is needed for impeding AI outbreaks, protecting the poultry industry, which provides the most important protein source for human consumption and minimizing the risk for an AI pandemic in humans.
Adenovirus Recombinant Vaccine
Recombinant human adenovirus (Ad) serotype 5 (Ad5)-derived vectors have been used for a variety of purposes including gene transfer in vitro, vaccination in vivo, and gene therapy. They can transfer genes to a broad spectrum of cell types, gene transfer is not dependent on active cell division, and high levels of transgene expression can be obtained. Humans have been safely and effectively immunized by administration of Ad5-vectored influenza vaccines (Van Kampen et al., 2005) . Gao et al. (2006) reported that chickens could be protected against H5N1 AI virus challenge following subcutaneous injection of this human Ad5 vector encoding an avian H5 HA. In both cases, the Ad5-vectored influenza vaccines were produced in human 293 cells, which intrinsically contaminate recombinant Ad5 stocks by generating replication-competent Ad (RCA) through homologous recombination between the Ad5 vector and the E1 region in the 293 genome (Zhu et al., 1999) . The RCA poses a biohazard to humans and may out-replicate the recombinant vectors during large-scale production. We have demonstrated that chickens can be protected against HPAI by in ovo administration of an RCA-free human Ad5 vector encoding avian H5 HA (Toro et al., 2007) . This vectored AI vaccine possesses no safety risk because of its replication incompetence, and the in ovo mode allows automated mass delivery.
Human Adenovirus Serotype 5-Derived Vector Transduces Chicken Cells and Elicits an Immune Response After In Vivo Vaccination
In 2003 
Construction of RCA-Free Recombinant Adenovirus Vectors Encoding the HA Gene of AI Virus
The Ad-vectored AI vaccines encoding either the AI virus H5 or H7 transgene were developed (Toro et al., 2007 (Toro et al., , 2008 . For the development of an H5 recombinant vaccine the A/turkey/Wisconsin/68 (A/tk/ WI/68) H5 HA gene was PCR-amplified from a plasmid template (Suarez and Schultz-Cherry, 2000) using a described previously primer pair (Toro et al., 2007) .
These primers contain sequences that anneal to the 5′ and 3′ ends of the HA gene, a eukaryotic ribosomal binding site immediately upstream from the initiation ATG codon, and unique restriction sites for subsequent cloning. The fragment containing the full-length HA gene was inserted into the HindIII-BamHI site of the shuttle plasmid pAdApt (provided by Crucell Holland BV, Leiden, the Netherlands) to generate the plasmid pAdApt-TW68.H5 with the HA gene under transcriptional control of the human cytomegalovirus (CMV) early promoter. An RCA-free, E1/E3-defective Ad5 vector encoding this H5 HA gene (AdTW68. H5) was subsequently constructed in human PER. C6 cells (provided by Crucell) by recombination following co-transfection of pAdApt-TW68.H5 with the Ad5 backbone plasmid pAdEasy1 (He et al., 1998) as described (Shi et al., 2001) . The Ad5 recombinant vaccine with the H7 transgene was developed similarly. In brief, a fragment containing the full-length H7 gene of the A/Ch/NY/13142-5/94 AI virus was inserted into the HindIII-BamHI site of the shuttle plasmid pAdApt to generate the plasmid pAdApt-NY94.H7. An RCAfree E1/E3-defective Ad5 vector encoding the H7 gene was subsequently constructed in human PER.C6 cells by co-transfection of pAdApt-NY94.H7 with the Ad5 backbone plasmid pJM17, followed by multiple cycles of plaque purification. Both the AdTW68.H5 and AdChNY94.H7 recombinant viruses were validated by DNA sequencing. Titers (ifu/mL) were determined by the Adeno-X rapid titer kit (BD Clontech; Mountain View, CA).
Protective Immunity Against AI Can Be Elicited in Chickens in a Single-Dose Regimen by In Ovo Vaccination with RCA-Free Human Ad5-Derived Vector Encoding Avian Influenza Hemagglutinin
The generated RCA-free Ad5 vector encoding the AI H5 HA (AdTW68.H5) was administered in ovo to specific-pathogen-free (SPF) chickens as described (Sharma and Burmester, 1982) to evaluate antibody responses and protection against challenge. The HI antibody titers in serum samples against the low pathogenic H5N9 A/ Tk/WI/68 strain were determined as described (Swayne et al., 1998) . We evaluated vaccine protection conferred by challenge with HPAI strains that differed distinctly in the deduced amino acid sequence from the H5 of the A/Tk/WI/68 strain expressed from the Ad5 vector: 1) HPAI A/Ch/Queretaro/19/95 H5N2 with 94%; and 2) HPAI A/Swan/Mongolia//244L/2005 H5N1 with 89% deduced HA amino acid sequence identity.
Overall, in ovo administration of RCA-free Ad-vectored AI vaccines induced robust antibody responses against the HA of AI virus in chickens, with geometric mean HI titers varying between 4.8 and 6.5 log 2 (Toro et al., 2007) . Figure 1 shows specific antibody levels (individual HI values and geometric means) achieved in chickens vaccinated in ovo during the course of different vaccination trials using vaccine doses varying from 10 7 to 10 9 ifu between trials. Even though measurements were made at different ages and different doses were used in the experiments, the mean antibody levels obtained in the birds were similar. As seen in Figure 1 , most trials resulted in 100% of the vaccinated hatched chickens exhibiting some level of antibody, only in one trial 14% of all vaccinated birds (2/14) were negative for HI antibody.
Our protection studies showed that all chickens (19/19) vaccinated in ovo survived the challenge with the HPAI A/chicken/Queretaro/95 (A/Ch/ Quer/19/95) strain (94% HA homology with vaccine). There was also a significant difference (P < 0.05) in the concentration of viral genomes of AI A/ Ch/Quer/19/95 between vaccinated and unvaccinated chickens 7 d after challenge. Absence of detectable viral RNA in immunized birds provides evidence that in ovo vaccination elicited an immune response capable of controlling AI virus shedding within a week. The HPAI A/Swan/Mongolia/244L/2005 H5N1 challenge resulted in death of all unvaccinated controls within 9 d postchallenge, whereas 68% (21/31) of the AdTW68. H5-vaccinated birds survived without clinical signs 10 d after the challenge. Notably, 7 birds in the immunized group with HI titers of ≥3 log 2 were still killed by this highly lethal H5N1 AI virus (89% HA homology to vaccine). These results suggested that extent of protection against HPAI viruses is associated with the degree of homology in amino acid sequence between the HA encoded by the Ad-vectored HA transgene and the HA of the HPAI challenge strain (Toro et al., 2007) . A logical follow-up of our studies with the H5 HA vaccine was to develop an Ad vector encoding an H7 HA. The generated RCA-free AdChNY94.H7 (described above) was administered either by the i.m. route to 29-d-old SPF chickens or in ovo to 18-d SPF embryonated eggs to evaluate antibody responses and protection against challenge. Control groups included chickens vaccinated with an Ad vector (AdCMV-tetC) encoding an irrelevant antigen (tetanus toxin C-fragment; Van Kampen et al., 2005) and chickens that were not exposed to Ad vectors. The HI antibody titers in serum samples were determined as described (Swayne et al., 1998) against the low pathogenic A/Tk/OR/71 (H7N3). Challenge was performed by choanal inoculation of 10 5.5 EID 50 of the H7N3 HPAI virus strain A/Ch/Chile/4957/02 (H7N3; Suarez et al., 2004) . The HA of this challenge strain has 92.3% deduced amino acid sequence similarity with the HA of the A/Ch/ NY/13142-5/94 strain expressed from the Ad5 vector. Similar to chickens vaccinated in ovo with AdTW68. H5, antibody levels in chickens vaccinated in ovo with AdChNY94.H7 achieved a median of 3 log 2 on d 25 and 5 log 2 on d 45 after hatch.
The HI antibody titers detected in chickens vaccinated i.m. with AdChNY94.H7 were greater than the values obtained after in ovo delivery of the same vaccine. Antibody titers in chickens immunized i.m. showed mean HI antibody titers of 7.6 log 2 on d 35 after vaccination. Viral RNA of AI strain A/Ch/Chile/4957/02 in challenged chickens was detectable in 1 immunized bird at 2 d after challenge but was detected in all but 2 nonimmunized control chickens. The survival rate of vaccinated chickens was 100% (11/11), whereas only 13.2% (2/11) of unvaccinated birds survived after challenge with HPAI strain A/Ch/Chile/4957/02 (H7N3). These results demonstrated that the newly developed AdChNY94.H7-vectored AI vaccine efficiently induced a specific antibody response both in chickens vaccinated in ovo and by the i.m. route. We also demonstrated that i.m. vaccinated chickens were protected against challenge with an HPAI H7N3 strain that caused severe mortality in the Chilean poultry industry in 2002. These results confirm that the RCA-free human Ad vector efficiently expresses different HA genes in chickens vaccinated via different routes.
Our previous work showed that chickens vaccinated with AdTW68.H5 with HI antibody titers of 5 log 2 were protected (100%) against challenge with the HPAI A/ch/Quer/19/95 (H5N2) strain. However AI viral genomes were detected until d 7 after challenge in those birds (Toro et al., 2007) . Chickens vaccinated with AdChNY94.H7 were also 100% protected against HPAI challenge, but in addition reduction of viral shedding was more pronounced. The difference may be explained by the fact that chickens vaccinated intramuscularly with AdChNY94.H7 had mean HI antibody titers of ~8.0 log 2 at the time of challenge, whereas chickens vaccinated in ovo with AdTW68.H5 had titers of ~5.0 log 2 . Greater antibody titers are likely the result of i.m. vaccination. Swayne et al. (2000a) showed for a fowl pox recombinant vaccine that preexisting immunity to the vector in the host precludes the establishment of protective immune responses against exogenous antigens expressed by the same vector upon vaccination. Thus, we were interested in determining whether chickens immunized in ovo with an Ad-vectored vaccine can be vaccinated posthatch with another Ad-vectored vaccine containing the same Ad backbone. In ovo immunization with AdTW68.H5 elicited HI antibody titers against AI strain A/Tk/WI/68 (H5N9) varying between 2 and 7 log 2 with a mean of 4.6 log 2 on d 27 of age. The same birds subsequently inoculated intramuscularly with AdChNY94.H7 at 27 d of age continued to increase (P < 0.0001) their H5 antibody levels, achieving values varying between 6 and 10 log 2 with a mean of 7.9 log 2 on d 52 of age. Vaccination with AdChNY94.H7 induced mean HI antibody levels of 4.0 log 2 against A/ Tk/OR/68 (H7N3) 25 d after vaccination (d 52 of age). These antibody titers (H7) significantly increased (P < 0.0001) with time achieving a mean of 8 log 2 on d 68 of age (41 d after vaccination). These results showed that in ovo vaccination with AdTW68.H5 does not impair an efficient response against the H7 HA after subsequent vaccination with the same Ad vector encoding a different HA (AdChNY94.H7) after hatch. A possible explanation for this result may be that the immune response against the nonreplicating Ad is rather limited in contrast to strong immune responses resulting from replicating viral vectors such as fowl pox virus (Swayne et al., 2000a) . From an applied perspective, this result is relevant because it demonstrates the feasibility of revaccinating chicken populations against a different AI HA with the same Ad-vector technology.
Codon optimization of the transgene has been shown to significantly improve the immune response in the host (Mossadegh et al., 2004; Ramakrishna et al., 2004) . Thus, a codon-optimized A/Tk/WI/68 H5 HA gene was synthesized with codons optimized to match the tRNA pool found in chicken cells. An Ad vector (AdTW68. H5 ck ) encoding the codon-optimized HA gene was constructed in human PER.C6 cells as described (Toro et al., 2007) and tested in chickens by the in ovo route. Our results showed that the AdTW68.H5 ck vector expressing the codon optimized synthetic HA gene was more potent in immunizing chickens than its nonoptimized counterpart. Greater anti-H5 antibody titers were detected in chickens vaccinated with AdTW68. H5 ck compared with titers in chickens vaccinated with AdTW68.H5. The use of synthetic genes instead of natural genes provides a great advantage for vaccine production because it is feasible to produce vaccines against virus strains causing outbreaks of disease in distant regions of the world without the necessity of importing dangerous strains or their genetic material to the vaccine production sites. In addition, optimization to the chicken codons improved the specific antibody responses of the vaccinated chickens.
The RCA-free Ad5 vectored AI vaccines can be produced safely and cost effectively in large-scale in the well-characterized PER.C6 cell line in serum-free suspension bioreactors (Lewis et al., 2006) in conjunction with chromatography-mediated purification (Konz et al., 2005) . Mass delivery to large chicken populations can be performed via routinely used automated in ovo injectors (Sharma and Burmester, 1982; Wakenell et al., 2002) in response to an emerging AI pandemic. This Ad5-vectored AI vaccine is in compliance with a DIVA strategy because the vector only encodes the viral HA. In contrast to live AI virus vaccines that may generate undesirable new reassortants with concurrently circulating wild influenza viruses (Hilleman, 2002) , it is not possible for the DNA genome of Ad5 to undergo reassortment with the segmented RNA genome of an influenza virus. The Ad5 vector system overcomes these issues, and the RCA-free Ad5 vector will not propagate even in human cells in the absence of the Ad E1 gene.
